Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and Rate of Patients Achieving the Treatment Goal
CRE NIS
A Cross-sectional Study to Survey the Awareness of Chinese National Adult Lipid Treatment Guideline (2007) and the Rate of Patients (on Treatment) Achieving the Hyperlipidaemia Treatment Goal With Crestor 5mg to 10mg for 8 Weeks
1 other identifier
observational
2,575
1 country
15
Brief Summary
This study is designed to survey the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists; To survey the control rate of the patients with dyslipidemia in "real world"; and to evaluate the percentage of hyperlipidemia patients who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007) following 8-week treatment by Crestor® 5mg or 10mg
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Oct 2008
Shorter than P25 for all trials
15 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 1, 2008
CompletedFirst Submitted
Initial submission to the registry
October 28, 2008
CompletedFirst Posted
Study publicly available on registry
October 29, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
July 1, 2009
CompletedAugust 7, 2009
August 1, 2009
October 28, 2008
August 6, 2009
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
the awareness rate of Chinese National Adult Lipid Treatment Guideline (2007) by cardiologists
1 time
the control rate of patients reaching target LDL-C level
8 weeks
Secondary Outcomes (2)
the percent change from baselines in TC, TG, HDL-C
8 weeks
the percentage of hyperlipidemia patients in different risk categories who achieved target LDL-C level according to the Chinese National Adult Lipid Treatment Guideline (2007)
8 weeks
Study Arms (2)
1
patients being diagnosed as dyslipidemia but not receiving Crestor®
2
hypercholesterolemia or mixed dyslipidemia and have been initiated treatment with Crestor®
Eligibility Criteria
Patients who has been diagnosed as hypercholesterolemia and decided by physician to use Crestor® 5mg or 10mg or other regimens (TLC or other lipid-lowering agents)
You may qualify if:
- Diagnosed as dyslipidemia by doctors
- Having lipids test and record within one months
- Diagnosed as hypercholesterolemia or mixed dyslipidaemias and has been prescribed Crestor® 5mg or 10mg
You may not qualify if:
- Unable or unwilling to provide the Inform Consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
Study Sites (15)
Research Site
Beijing, Beijing Municipality, China
Research Site
Chenzhen, Guangdong, China
Research Site
Guangzhou, Guangdong, China
Research Site
Harbin, Heilongjiang, China
Research Site
Zhengzhou, Henan, China
Research Site
Nanjing, Jiangsu, China
Research Site
Shenyang, Liaoning, China
Research Site
Jinan, Shandong, China
Research Site
Qingdao, Shandong, China
Research Site
Shanghai, Shanghai Municipality, China
Research Site
Xi’an, Shanxi, China
Research Site
Chengdu, Sichuan, China
Research Site
Tianjin, Tianjin Municipality, China
Research Site
Hangzhou, Zhejiang, China
Reseearch Site
Ningbo, Zhejiang, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Karen Atkin
Astrazeneca China R&D
- PRINCIPAL INVESTIGATOR
Zhu Junren
Fudan University
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 28, 2008
First Posted
October 29, 2008
Study Start
October 1, 2008
Study Completion
July 1, 2009
Last Updated
August 7, 2009
Record last verified: 2009-08